Willow Pb Ratio vs Capex To Revenue Analysis

WLLW Stock

CAD 0.08 0.01 5.88%

Willow Biosciences financial indicator trend analysis is more than just analyzing Willow Biosciences current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Willow Biosciences is a good investment. Please check the relationship between Willow Biosciences Pb Ratio and its Capex To Revenue accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Willow Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Pb Ratio vs Capex To Revenue

Pb Ratio vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Willow Biosciences Pb Ratio account and Capex To Revenue. At this time, the significance of the direction appears to have no relationship.

The correlation between Willow Biosciences' Pb Ratio and Capex To Revenue is 0.03. Overlapping area represents the amount of variation of Pb Ratio that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Willow Biosciences, assuming nothing else is changed. The correlation between historical values of Willow Biosciences' Pb Ratio and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pb Ratio of Willow Biosciences are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Pb Ratio i.e., Willow Biosciences' Pb Ratio and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

0.03

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Pb Ratio

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Willow Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Willow Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Willow Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Willow Biosciences' Selling General Administrative is very stable compared to the past year. As of the 4th of December 2024, Enterprise Value is likely to grow to about 14.8 M, while Tax Provision is likely to drop (5.2 K).

Willow Biosciences fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Common Stock Total Equity	Common Stock Shares Outstanding	Total Liab	Common Stock	Total Assets	Net Debt	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Other Current Assets	Total Current Assets	Other Stockholder Equity	Property Plant And Equipment Net	Non Current Assets Total	Property Plant And Equipment Gross	Short Long Term Debt Total	Non Currrent Assets Other	Short Term Debt	Other Assets	Property Plant Equipment
Other Current Liab		0.34	0.57	-0.45	0.73	0.54	0.54	0.51	0.71	-0.67	0.17	0.67	0.7	0.82	0.67	0.65	0.71	0.14	0.45	0.47	0.57	0.0	-0.08	0.84	0.6	0.47
Total Current Liabilities	0.34		0.5	-0.66	0.5	0.62	0.51	0.66	0.63	-0.53	0.83	0.56	0.58	0.33	0.21	0.45	0.59	0.09	0.67	0.57	0.47	0.29	-0.13	0.41	0.04	0.57
Total Stockholder Equity	0.57	0.5		-0.47	0.49	0.6	0.2	0.6	0.88	-0.87	0.32	0.87	0.89	0.44	0.07	0.49	0.88	0.27	0.55	0.56	0.57	-0.06	-0.13	0.56	0.35	0.55
Retained Earnings	-0.45	-0.66	-0.47		-0.88	-0.98	-0.4	-0.99	-0.57	0.5	-0.31	-0.56	-0.59	-0.26	-0.2	-0.92	-0.61	-0.45	-0.43	-0.27	-0.89	-0.48	0.3	-0.64	0.0	-0.37
Common Stock Total Equity	0.73	0.5	0.49	-0.88		0.9	0.46	0.89	0.61	-0.54	0.14	0.6	0.62	0.55	0.47	0.95	0.63	0.35	0.44	0.35	0.91	0.51	-0.18	0.86	0.31	0.38
Common Stock Shares Outstanding	0.54	0.62	0.6	-0.98	0.9		0.39	0.99	0.66	-0.6	0.26	0.66	0.69	0.36	0.22	0.93	0.7	0.46	0.48	0.35	0.93	0.41	-0.29	0.71	0.06	0.46
Total Liab	0.54	0.51	0.2	-0.4	0.46	0.39		0.39	0.65	-0.6	0.39	0.61	0.59	0.52	0.88	0.39	0.6	0.07	0.74	0.61	0.15	0.02	-0.13	0.44	0.48	0.72
Common Stock	0.51	0.66	0.6	-0.99	0.89	0.99	0.39		0.66	-0.6	0.32	0.66	0.69	0.32	0.2	0.92	0.7	0.45	0.49	0.35	0.92	0.44	-0.29	0.67	0.06	0.44
Total Assets	0.71	0.63	0.88	-0.57	0.61	0.66	0.65	0.66		-0.97	0.44	0.98	0.98	0.6	0.49	0.58	0.98	0.25	0.8	0.74	0.52	-0.03	-0.16	0.65	0.5	0.78
Net Debt	-0.67	-0.53	-0.87	0.5	-0.54	-0.6	-0.6	-0.6	-0.97		-0.35	-1.0	-0.99	-0.47	-0.47	-0.57	-0.99	-0.2	-0.67	-0.59	-0.46	0.13	0.14	-0.59	-0.55	-0.69
Accounts Payable	0.17	0.83	0.32	-0.31	0.14	0.26	0.39	0.32	0.44	-0.35		0.36	0.38	0.13	0.12	0.09	0.38	-0.16	0.53	0.47	0.1	0.18	0.04	-0.02	-0.01	0.43
Cash	0.67	0.56	0.87	-0.56	0.6	0.66	0.61	0.66	0.98	-1.0	0.36		0.99	0.48	0.47	0.62	0.99	0.23	0.7	0.61	0.52	-0.06	-0.16	0.62	0.53	0.7
Cash And Short Term Investments	0.7	0.58	0.89	-0.59	0.62	0.69	0.59	0.69	0.98	-0.99	0.38	0.99		0.49	0.44	0.64	1.0	0.25	0.67	0.58	0.56	-0.08	-0.19	0.63	0.49	0.67
Net Receivables	0.82	0.33	0.44	-0.26	0.55	0.36	0.52	0.32	0.6	-0.47	0.13	0.48	0.49		0.61	0.34	0.5	0.1	0.55	0.72	0.35	0.03	0.05	0.74	0.59	0.57
Non Current Liabilities Total	0.67	0.21	0.07	-0.2	0.47	0.22	0.88	0.2	0.49	-0.47	0.12	0.47	0.44	0.61		0.36	0.45	-0.05	0.52	0.45	0.1	0.02	-0.02	0.53	0.65	0.51
Other Current Assets	0.65	0.45	0.49	-0.92	0.95	0.93	0.39	0.92	0.58	-0.57	0.09	0.62	0.64	0.34	0.36		0.66	0.4	0.31	0.15	0.92	0.38	-0.26	0.77	0.18	0.3
Total Current Assets	0.71	0.59	0.88	-0.61	0.63	0.7	0.6	0.7	0.98	-0.99	0.38	0.99	1.0	0.5	0.45	0.66		0.26	0.67	0.58	0.57	-0.07	-0.19	0.65	0.49	0.67
Other Stockholder Equity	0.14	0.09	0.27	-0.45	0.35	0.46	0.07	0.45	0.25	-0.2	-0.16	0.23	0.25	0.1	-0.05	0.4	0.26		0.3	0.15	0.47	-0.07	-0.41	0.4	-0.16	0.22
Property Plant And Equipment Net	0.45	0.67	0.55	-0.43	0.44	0.48	0.74	0.49	0.8	-0.67	0.53	0.7	0.67	0.55	0.52	0.31	0.67	0.3		0.92	0.32	0.11	-0.23	0.48	0.26	0.92
Non Current Assets Total	0.47	0.57	0.56	-0.27	0.35	0.35	0.61	0.35	0.74	-0.59	0.47	0.61	0.58	0.72	0.45	0.15	0.58	0.15	0.92		0.23	0.11	-0.02	0.45	0.37	0.87
Property Plant And Equipment Gross	0.57	0.47	0.57	-0.89	0.91	0.93	0.15	0.92	0.52	-0.46	0.1	0.52	0.56	0.35	0.1	0.92	0.57	0.47	0.32	0.23		0.47	-0.3	0.77	0.01	0.27
Short Long Term Debt Total	0.0	0.29	-0.06	-0.48	0.51	0.41	0.02	0.44	-0.03	0.13	0.18	-0.06	-0.08	0.03	0.02	0.38	-0.07	-0.07	0.11	0.11	0.47		0.21	0.15	-0.04	-0.06
Non Currrent Assets Other	-0.08	-0.13	-0.13	0.3	-0.18	-0.29	-0.13	-0.29	-0.16	0.14	0.04	-0.16	-0.19	0.05	-0.02	-0.26	-0.19	-0.41	-0.23	-0.02	-0.3	0.21		-0.25	0.38	-0.12
Short Term Debt	0.84	0.41	0.56	-0.64	0.86	0.71	0.44	0.67	0.65	-0.59	-0.02	0.62	0.63	0.74	0.53	0.77	0.65	0.4	0.48	0.45	0.77	0.15	-0.25		0.42	0.46
Other Assets	0.6	0.04	0.35	0.0	0.31	0.06	0.48	0.06	0.5	-0.55	-0.01	0.53	0.49	0.59	0.65	0.18	0.49	-0.16	0.26	0.37	0.01	-0.04	0.38	0.42		0.27
Property Plant Equipment	0.47	0.57	0.55	-0.37	0.38	0.46	0.72	0.44	0.78	-0.69	0.43	0.7	0.67	0.57	0.51	0.3	0.67	0.22	0.92	0.87	0.27	-0.06	-0.12	0.46	0.27

Click cells to compare fundamentals

Willow Biosciences Account Relationship Matchups

Willow Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	1.8M	1.6M	1.4M	1.7M	1.8M	944.0K
Total Stockholder Equity	22.0M	(559K)	29.7M	16.4M	3.4M	3.8M
Retained Earnings	(53.8M)	(87.7M)	(93.8M)	(108.7M)	(121.7M)	(115.6M)
Common Stock Shares Outstanding	72.1M	82.0M	120.0M	123.7M	124.2M	130.5M
Total Liab	11.9M	22.4M	5.3M	1.8M	3.2M	2.5M
Common Stock	72.6M	83.2M	118.0M	118.1M	118.2M	124.1M
Total Assets	33.9M	21.9M	35.0M	18.1M	6.7M	7.2M
Net Debt	(18.4M)	(15.0M)	(29.3M)	(10.3M)	(989K)	(1.0M)
Accounts Payable	1.1M	978K	757K	1.1M	635K	650.4K
Cash	19.6M	15.9M	30.1M	11.0M	3.1M	4.0M
Cash And Short Term Investments	19.7M	15.9M	30.1M	15.0M	3.2M	4.2M
Net Receivables	654.2K	289K	89K	282K	166K	127.4K
Liabilities And Stockholders Equity	33.9M	21.9M	35.0M	18.1M	6.7M	7.2M
Other Current Assets	201.3K	561K	679K	643K	619K	650.0K
Total Current Assets	20.8M	17.0M	31.3M	16.2M	4.2M	4.5M
Other Stockholder Equity	3.3M	4.3M	5.9M	7.3M	7.3M	6.9M
Property Plant And Equipment Net	6.7M	4.7M	3.7M	1.9M	2.4M	2.7M
Non Current Assets Total	13.1M	4.8M	3.7M	1.9M	2.5M	3.2M
Property Plant Equipment	6.5M	4.7M	3.6M	1.9M	2.2M	2.6M
Short Term Investments	90.9K	561K	679K	4.0M	20K	19K
Net Tangible Assets	835.0K	15.5M	(624K)	29.6M	34.1M	35.8M

Pair Trading with Willow Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Willow Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Willow Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Willow Stock

0.73

CMC

Cielo Waste Solutions

Pair Corr

Moving against Willow Stock

0.74

LQWD

LQwD FinTech Corp

Pair Corr

The ability to find closely correlated positions to Willow Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Willow Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Willow Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Willow Biosciences to buy it.

The correlation of Willow Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Willow Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Willow Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Willow Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Willow Stock

Balance Sheet is a snapshot of the financial position of Willow Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Willow Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Willow Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Willow currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Willow Pb Ratio vs Capex To Revenue Analysis

Pb Ratio vs Capex To Revenue

Pb Ratio vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Pb Ratio

Capex To Revenue

Willow Biosciences fundamental ratios Correlations

Willow Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Willow Biosciences fundamental ratios Accounts

Pair Trading with Willow Biosciences

Moving together with Willow Stock

Moving against Willow Stock

Other Information on Investing in Willow Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 0.99	Common Stock Shares Outstanding
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Cash	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets

Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Common Stock	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Net Debt	- 0.97	Total Assets